🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

26 results for “Revolution” Clear

  1. DARAXONRASIB (RMC-6236), DARAXONRASIB (RMC-6236)

    Revolution Medicines

    Resected Pancreatic Ductal Adenocarcinoma (PDAC)

    phase 3 small molecule active

    1 trial

  2. DARAXONRASIB (RMC-6236), DOCETAXEL, DARAXONRASIB (RMC-6236)

    Revolution Medicines

    non-small cell lung cancer

    phase 3 small molecule active

    1 trial

  3. DARAXONRASIB (RMC-6236), GEMCITABINE HYDROCHLORIDE, PACLITAXEL ALBUMIN-BOUND, GEMCITABINE HYDROCHLORIDE, OXALIPLATIN, GEMCITABINE HYDROCHLORIDE, DARAXONRASIB (RMC-6236), GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE, IRINOTECAN, IRINOTECAN HYDROCHLORIDE, FOLINIC ACID, FLUOROURACIL, GEMCITABINE HYDROCHLORIDE

    Revolution Medicines

    Metastatic Pancreatic Ductal Adenocarcinoma

    phase 3 small molecule active

    1 trial

  4. RMC-6236

    Revolution Medicines

    Pancreatic Cancer

    phase 3 small molecule active

    1 trial

  5. daraxonrasib

    Revolution Medicines

    NSCLC (Non-small Cell Lung Cancer)

    phase 3 small molecule active

    1 trial

  6. daraxonrasib

    Revolution Medicines

    Pancreatic Cancer

    phase 3 small molecule active

    2 trials

  7. Daraxonrasib

    Revolution Medicines

    Advanced Solid Tumors

    phase 2 small molecule active

    1 trial

  8. Elironrasib

    Revolution Medicines

    Non-Small Cell Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  9. PEMBROLIZUMAB, DARAXONRASIB (RMC-6236), CARBOPLATIN, DARAXONRASIB (RMC-6236), PEMETREXED, CISPLATIN, RMC-9805

    Revolution Medicines

    Lung Cancer

    phase 2 small molecule active

    1 trial

  10. RMC-4630

    Revolution Medicines

    Non-Small Cell Lung Cancer

    phase 2 small molecule completed

    1 trial

  11. RMC-4630

    Revolution Medicines

    Solid Tumor

    phase 2 small molecule completed

    1 trial

  12. RMC-6236

    Revolution Medicines

    Non-small Cell Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  13. RMC-6236

    Revolution Medicines

    Colorectal Cancer

    phase 2 small molecule active

    1 trial

  14. RMC-6291

    Revolution Medicines

    Non-Small Cell Lung Cancer, NSCLC

    phase 2 small molecule active

    2 trials

  15. RMC-9805

    Revolution Medicines

    Lung Cancer

    phase 2 small molecule active

    1 trial

  16. TNG462

    Revolution Medicines

    PDAC

    phase 2 small molecule active

    1 trial

  17. Vociprotafib

    Revolution Medicines

    Metastatic Neoplasm

    phase 2 small molecule terminated

    1 trial

  18. A study to see how combination of RMC-6291 and RMC-6236 is tolerated in multiple different dosages in participants with Advanced KRASG12C-mutated Solid Tumors

    Revolution Medicines

    Participants with Advanced KRASG12C-Mutated Solid Tumors

    phase 1 other active

    1 trial

  19. Pemetrexed STADA 25 mg/ml Konzentrat zur Herstellung einer Infusionslösung, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Pemetrexed Fresenius Kabi 100 mg powder for concentrate for solution for infusion, Pemetrexed Fresenius Kabi 100 mg powder for concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, RMC-6236, Cisplatinum Accord, 1 mg/ml, koncentrat do sporządzania roztworu do infuzji., CARBOPLATIN-EBEWE, 10 MG/ML, KONCENTRAT DO SPORZĄDZANIA ROZTWORU DO

    Revolution Medicines

    Lung Cancer

    phase 1 small molecule active

    1 trial

  20. Pemetrexed Synthon 25 mg/ml, concentraat voor oplossing voor infusie, DARAXONRASIB (RMC-6236), Pemetrexed Fresenius Kabi 100 mg powder for concentrate for solution for infusion, Cisplatin Hikma 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Carboplatin Kabi 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, DARAXONRASIB (RMC-6236), Cisplatinum Accord, 1 mg/ml, koncentrat do sporządzania roztworu do infuzji., CISPLATIN-EBEWE, 1 MG/ML, KONCENTRAT DO SPORZĄDZANIA ROZTWORU DO INFUZJI, Pemetre

    Revolution Medicines

    Lung Cancer

    phase 1 small molecule active

    1 trial

  21. Phase 1/1b, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects with Advanced KRASG12C Mutant Solid Tumors.

    Revolution Medicines

    Non-Small Cell Lung Cancer (NSCLC), Pancreatic Ductal Adenocarcinoma, Advanced Solid Tumor, Colorectal Cancer (CRC)

    phase 1 other active

    1 trial

  22. RMC-4630

    Revolution Medicines

    Solid Tumors

    phase 1 small molecule active

    1 trial

  23. RMC-5127

    Revolution Medicines

    Non-small Cell Lung Cancer (NSCLC)

    phase 1 small molecule active

    1 trial

  24. RMC-5552

    Revolution Medicines

    Solid Tumors

    phase 1 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources